USA flag logo/image

An Official Website of the United States Government

CDX-301 and Plerixafor Combination in Stem Cell Mobilization for Transplantation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43DK100139
Solicitation Year:
2013
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA12-088
Small Business Information
COGNOSCI, INC.
79 T. W. Alexander Drive RESEARCH TRIANGLE PARK, NC 27709-2076
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: CDX-301 and Plerixafor Combination in Stem Cell Mobilization for Transplantation
Agency: HHS
Contract: 1R43DK100139-01
Award Amount: $225,067.00
 

Abstract:

DESCRIPTION (provided by applicant): Diabetic peripheral neuropathy (DPN) is one of the most common and devastating complications of diabetes mellitus, affecting more than 50% of diabetic patients, and is the leading cause of foot amputation. DPN, characterized by peripheral axonal degeneration and demyelination, can be disabling and extremely painful, causing significant loss of functional abilities and decreasing quality of life. Currently, the only effectve treatments are glucose control and pain management. Although glucose control and some preventive strategies have been proposed to attenuate the development of DPN, none of them has demonstrated neuroreparative activity for existing neuropathy. Therefore, a neurorestorative strategy to repair damaged peripheral nerves is still critically needed to alleviate the persistent symptoms of established DPN. Cognosci has innovatively created and characterized a series of peptides derived from human apolipoprotein E (apoE), which we designate as COG compounds, from which we have identified a lead compound COG112 for inflammatory neurodegenerative diseases. Extensive studies have demonstrated that COG112 and other COG compounds exert potent neuroprotective activities against oxidative stress and inflammatory response, as well as neuroreparative activities both in vitro and in vivo. We have also obtained data showing that COG112 can significantly prevent axonal degeneration and promote axonal regeneration and remyelination in a sciatic nerve crush model. A similar neuroprotective effect has been validated in animal models of a variety of neurological disorders such as traumatic brain injury, spinal cord injury, subarachnoid hemorrhage and multiple sclerosis, implicating a therapeutic efficacy for these diseases. Because apoE has been considered as one of the genetic factors of diabetes and DPN, our preliminary data support that COG112 may demonstrate therapeutic efficacy on DPN by protecting peripheral nerves from hyperglycemia-mediated oxidative and inflammatory damages and promoting neuroregeneration. Therefore, we will test our hypothesis through both in vitro and in vivo models of DPN in the following specific aims: 1) To validate the potential neuroprotective effect of COG112 on a high glucose-induced neuronaldeath and axonal damage in primary dorsal root ganglion (DRG) cultures and the neuroregenerative effect on neurite outgrowth of DRGs from adult streptozocin (STZ)-induced diabetic rats. 2) To determine if COG112 exerts neuroprotective and neurorestorativeeffects in vivo by functional and histological examination in a DPN model of BKS db/db mice. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Our overall goal is to develop a novel neurorestorative therapy for diabetic neuropathy with not only protective potential, but also with reparative capability. Completion of this Phase I study will enable us to obtain proof of concept that apoE-mimetic COG112 can antagonize hyperglycemic oxidative stress, interfere with noxious inflammatory responses, andpromote axonal regeneration to maximize functional recovery. If substantiated by this study, COG112 may represent a first-in-class neurorestorative therapy for diabetic peripheral neuropathy that can satisfy this critically unmet medical need. The strategymay potentially be useful for other complications of diabetes such as diabetic retinopathy.

Principal Investigator:

Feng-qiao Li
919-765-0028
fli@cognosci.com

Business Contact:

Michael P. Vitek
919-765-0028
mikevitek@cognosci.com
Small Business Information at Submission:

COGNOSCI, INC.
79 T. W. Alexander Drive RESEARCH TRIANGLE PARK, NC 27709-2076

EIN/Tax ID: 156220852
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No